Town Hall Teleconference for Non-Group Health Plan Arrangements scheduled

CMS will be hosting a NGHP Policy and Technical Support related teleconference event on July 28, 2015. Topic: Upcoming transition of a portion of the NGHP recovery workload to the Commercial Repayment Center and policy and technical questions regarding Section 111 reporting.

Date: July 28, 2015
Call-in time: 1:00 PM – 2:00 PM EST
Call-in line: (800)603-1774
Pass Code: Section 111
Submit Questions: PL110_173SEC111-comments@cms.hhs.gov

Begin dialing in approximately 20 minutes before the call start time.

Xtampza ER® for Chronic Low Back Pain

In prior blogs, we have talked about the release of abuse-deterrent opioids Embeda® and Targiniq ER® (http://blog.nqbp.com/?p=790) and their potential impact in the workers’ compensation industry. Projected for release in the latter part of 2015, Xtampza ER® comes with an interesting FDA indication, which may have significant impact on claims.

Xtampza ER® (Oxycodone ER) capsules, manufactured by Collegium Pharmaceuticals, will be the first product manufactured with their proprietary DETERx® technology which will make it difficult to misuse or abuse the medication. In addition, Xtampza ER® users will be able to open the capsule and sprinkle the contents on soft foods or through a feeding tube if they have trouble swallowing (commonly known as dysphagia).

What makes Xtampza ER® unique is its FDA labeled indication in the treatment of chronic pain, including low back pain, for which a majority of its pre-approval studies were conducted. Although most users of this medication may be those with dysphagia, the question is will we see increased claims in workers’ compensation due to its indication and the relationship with chronic low back pain? As we have said many times, only time will tell, but it is certainly something to keep an eye on especially during the latter part of 2015.

As this product has not been released, no pricing is available at this time.

More information can be found at:

http://www.collegiumpharma.com/news/2015/03/collegium-pharmaceutical-to-present-xtampza-er-pivotal-phase-iii-data-at-the-2015-american-academy-of-pain-medicine-annual-meeting

http://drugdelivery.pharmaceutical-business-review.com/news/collegium-seeks-fda-approval-for-xtampza-er-to-treat-chronic-pain-161214-4469635

http://money.cnn.com/news/newsfeeds/articles/globenewswire/10137647.htm

References:

1. FDA.gov
2. Collegium Pharmaceuticals Press Release February 2015

CMS Implementing Optional MFA Services on the MSPRP

As part of the Strengthening Medicare and Repaying Taxpayers (SMART) Act, the Centers for Medicare & Medicaid Services (CMS) will be implementing optional MFA services on the MSPRP. MFA is the use of two or more different authentication factors to verify the identity of an end user. Verified users will have access to view unmasked claim data on the Portal.

Non debtors will still need to have a Verified Proof of Representation or Consent to Release authorization to perform actions on cases. Please note that MFA and the associated identity proofing process will be optional to portal users. Portal users may continue to use the portal without going through the MFA process but will not have the benefit of viewing un-masked data.

MFA is scheduled to be available beginning on July 13, 2015. Updated user guides and training materials will be available on CMS.gov and within the portal upon implementation.